TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01406808

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: genetic risk score for coronary risk factors
Description: genetic risk score based on coronary artery disease genetic risk variants (SNPs)
Study: NCT02852811

Intervention type: OTHER
Group type: OTHER
Intervention: Group education
Description: Intervention involving two education session with topics common in menopause transition.
Study: NCT00308919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST09
Description: Treatment with WST09 Vascular Photodynamic therapy
Study: NCT03447977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical
Description: cervical spine manual therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical
Description: cervical spine manual therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic
Description: thoracic spine manual therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: exercises for pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: exercises for pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: exercises for pain
Study: NCT02456675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB040093 Monotherapy
Description: INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB040093
Description: INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: The dose of itacitinib will be given orally once daily (QD).
Study: NCT00296023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT00857298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be \~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
Study: NCT01828385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate + rocuronium + sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline + rocuronium + sugammadex
Study: NCT03179059

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at Baseline
Description: Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at Baseline
Description: Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy test at follow up survey
Description: We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
Study: NCT00631397

Intervention type: DEVICE
Intervention: Ultrasound machine
Description: Weekly Bone Density measurements using the Sonometer
Study: NCT03937232

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cross-Education
Description: Home exercise program + usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Visual Feedback
Description: Home exercise program + usual care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Visual Feedback
Description: Home exercise program + usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
Study: NCT02731456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude exposure
Description: altitude exposure
Study: NCT04218552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD209
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD209
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD209
Description: PO, Once daily(QD), 8weeks
Study: NCT02787733

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of 500mg divided over two capsules
Study: NCT01058902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg
Description: Aspirin 75 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75 mg
Description: Aspirin 75 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no aspirin
Description: nothing
Study: NCT04218552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AD209
Description: PO, Once daily(QD), 8weeks
Study: NCT01058902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no aspirin
Description: nothing
Study: NCT04218552

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine low
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine low
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine high
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine high
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: PO, Once daily(QD), 8weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telmisartan
Description: PO, Once daily(QD), 8weeks
Study: NCT02182466

Intervention type: DEVICE
Intervention: Colon capsule endoscopy
Study: NCT04554992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID 19 Convalescent Plasma
Description: COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
Study: NCT00622804

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Billroth-II (B-II)
Description: After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux en Y gastrojejunostomy (RY-GJ)
Description: After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: uncut Roux en Y gastrojejunostomy
Description: After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
Study: NCT02917824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity IMT
Description: 30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity IMT
Description: 30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
Study: NCT01371877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D3
Description: Vitamin D 4000 IU per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Vitamin D3
Description: Vitamin D 600 IU per day
Study: NCT00936130

Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic gastric banding
Description: Laparoscopic gastric banding surgery

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy surgery

Intervention type: BEHAVIORAL
Intervention: Low Calorie Diet
Description: Low Calorie Diet Program
Study: NCT01343667

Intervention type: DEVICE
Group type: OTHER
Intervention: Gore Flow Reversal System
Description: Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting

Intervention type: DEVICE
Group type: OTHER
Intervention: Gore Embolic Filter
Description: Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
Study: NCT00532272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole ,Goserelin
Description: Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole ,Goserelin
Description: Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
Study: NCT02232152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00503997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.
Study: NCT01131039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Bevacizumab
Description: Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression
Study: NCT03410732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: activated DCs
Description: autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical surgery only
Description: Only radical surgery is given to the control group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery only
Description: Only radical surgery is given to the control group
Study: NCT00844480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: zoledronic acid, 5mg, iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv
Study: NCT01700738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric ring surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional help
Study: NCT03729414

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucopexy with Doppler artery ligation
Description: Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mucopexy without Doppler artery ligation
Description: Hemorrhoids will be treated by mucopexy alone performed in all quadrants
Study: NCT02906033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New perioperative practice model
Description: The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
Study: NCT01286194

Intervention type: DRUG
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium 10 mg orally every day for 14 days
Study: NCT01923844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exogenous surfactant
Description: Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached \> 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exogenous surfactant
Description: Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached \> 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
Study: NCT02071082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Study: NCT03619824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Definitive IMRT of 66-70Gy will be given in six to seven weeks.
Study: NCT00691639

Intervention type: OTHER
Intervention: Blood Collection Only
Description: Blood Collection Only
Study: NCT01069237

Intervention type: DEVICE
Intervention: OPTI-FREE RepleniSH
Description: Multi-Purpose Solution for soft contact lenses

Intervention type: DEVICE
Intervention: Clear Care
Description: Lens Care Solution for contact lenses
Study: NCT04796883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hanita Glaucoma shunt Ver.3.2
Description: The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.
Study: NCT01474031

Intervention type: OTHER
Intervention: Biomechanics
Description: * Time interval: pre-op - 3m - 6m - 12m~* Assessment of all subjects:~  * XR~ * Gait analysis with surface EMG and trunk markers:~    * Unipodal standing: 3 trials Right and 3 trials Left on FP~   * Level walking: 3 trials Right and 3 trials Left on FP~   * Chair rise: 3 trials, both legs on FP~   * Stair ascent: 3 trials Right and 3 trials Left on first FP~   * Stair descent: 3 trials Right and 3 trials Left on first FP~   * Squat: 3 trials, both legs on FP~ * Bipodal squat: 3 trials Right and 3 trials Left on FP~* Functional scores (HHS, UCLA, HOOS, SF-36)

Intervention type: OTHER
Intervention: Biomechanics
Description: * Time interval: pre-op - 3m - 6m - 12m~* Assessment of all subjects:~  * XR~ * Gait analysis with surface EMG and trunk markers:~    * Unipodal standing: 3 trials Right and 3 trials Left on FP~   * Level walking: 3 trials Right and 3 trials Left on FP~   * Chair rise: 3 trials, both legs on FP~   * Stair ascent: 3 trials Right and 3 trials Left on first FP~   * Stair descent: 3 trials Right and 3 trials Left on first FP~   * Squat: 3 trials, both legs on FP~ * Bipodal squat: 3 trials Right and 3 trials Left on FP~* Functional scores (HHS, UCLA, HOOS, SF-36)
Study: NCT01276691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 81 mg enteric coated aspirin
Description: 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 81 mg enteric coated aspirin
Description: 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 81 mg enteric coated aspirin
Description: 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 81 mg enteric coated aspirin
Description: 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting